- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Department of Pharma invites fresh applications under PLI scheme for bulk drugs

New Delhi: The Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers has invited applications from the Active Pharmaceutical Ingredients (API) manufacturers and eligible industries under the Production Linked Incentive (PLI) scheme for bulk drugs.
The invited applications are for the eligible products under the PLI Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and APIs in the country.
The department is seeking applications for several unsubscribed or partially subscribed products. These include important fermentation and chemical synthesis-based drugs such as Erythromycin Thiocyanate, Neomycin, Gentamycin, Clindamycin Base, Streptomycin, Tetracycline, among others.
Each eligible product comes with a set minimum annual production capacity and a maximum number of applicants that can be selected. For instance, up to two applicants will be selected for products like Gentamycin and Neomycin, while four manufacturers can apply for Ciprofloxacin and 2-Methyl (5) Nitro Imidazole.
Applicants must meet key conditions of the scheme, such as allocation according to available capacities, incentive ceiling in respect of products and limit of incentive up to the production tenure, i.e., up to FY 2027-28 for chemical synthesis products and up to FY 2028-29 for fermentation-based products.
Further, applicants or their group companies, including subsidiaries who had applied earlier under the scheme for the said unsubscribed and partially subscribed products and were granted approval, but who subsequently withdrew from the scheme or whose approval was cancelled in line with clause 12.11 of the scheme guidelines or owing to nonperformance, are not eligible to apply for the same eligible product.
Accordingly, applications are invited for the following eligible products:
S. No. | Target segment | Name of eligible product | Minimum annual production capacity as per scheme guidelines (in MT) | Total available production capacity (in MT) | Maximum no. of applicants to be selected |
1 | Key Fermentation based KSMs/Drug Intermediates | Erythromycin Thiocyanate (TIOC) | 800 | 1600 | 2 |
2 | Fermentation based niche KSMs/Drug Intermediates/APIs | Neomycin | 80 | 160 | 2 |
3 | Fermentation based niche KSMs/Drug Intermediates/APIs | Gentamycin | 40 | 80 | 2 |
4 | Fermentation based niche KSMs/Drug Intermediates/APIs | Clindamycin Base | 60 | 120 | 2 |
5 | Fermentation based niche KSMs/Drug Intermediates/APIs | Streptomycin | 50 | 100 | 2 |
6 | Fermentation based niche KSMs/Drug Intermediates/APIs | Tetracycline | 200 | 400 | 2 |
7 | Key Chemical Synthesis based KSMs/Drug Intermediates | 2-Methyl (5) Nitro Imidazole (2MNI) | 800 | 3200 | 4 |
8 | Other Chemical Synthesis based KSMs/Drug Intermediates/APIs | Ciprofloxacin | 150 | 600 | 4 |
9 | Other Chemical Synthesis based KSMs/Drug Intermediates/APIs | Diclofenac Sodium | 175 | 175 | 1 |
10 | Key Chemical Synthesis based KSMs/Drug Intermediates | Dicyandiamide (DCDA) | 8000 | 24000 | 3 |
11 | Key Chemical Synthesis based KSMs/Drug Intermediates | 1,1 Cyclohexane Diacetic Acid (CDA) | 1500 | 1500 | 1 |
The eligible applicants may apply through online mode only (https://plibulkdrugs.ifciltd.com) from 15.05.2025 to 14.06.2025. Detailed guidelines of the scheme and necessary corrigendum are available at https://pharma-dept.gov.in/schemes.
The last date of receipt of complete application is 14.06.2025.
For more details, check out the full story on the link mentioned below:
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751